Version May 2024
Dry eye disease: Ophthalmic: Instill 1 drop into affected eye(s) 4 times daily.
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
Refer to adult dosing.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
1% to 10%: Ophthalmic: Blurred vision (1% to 3%), conjunctival erythema (1% to 3%)
There are no contraindications listed in the manufacturer's labeling.
Special populations:
• Contact lens wearers: Remove contact lenses prior to administration and wait at least 30 minutes before reinserting.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Ophthalmic [preservative free]:
Miebo: 1.338 g/mL (3 mL)
No
Solution (Miebo Ophthalmic)
1.338 g/mL (per mL): $308.40
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Ophthalmic: For topical ophthalmic use only. Remove contact lenses prior to administration and wait at least 30 minutes before reinserting. Do not touch the eye or surrounding area or any surface with the dropper tip to avoid contamination.
Dry eye disease: Treatment of the signs and symptoms of dry eye disease.
None known.
There are no known significant interactions.
Adverse events were not observed in reproduction studies conducted in rats using oral perfluorohexyloctane in doses up to 162 times the equivalent recommended human ophthalmic dose (RHOD). Maternal toxicity and adverse pregnancy outcomes were observed in reproduction studies conducted in rabbits using oral perfluorohexyloctane at all doses studied, the lowest dose was 41 times the RHOD.
It is not known if perfluorohexyloctane is present in breast milk.
According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.
Perfluorohexyloctane is semifluorinated alkane that forms a monolayer at the air-liquid interface of the tear film thereby reducing evaporation.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
